Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. (ACB) is a globally recognized leader in medical and recreational cannabis production, operating advanced facilities that meet stringent international standards. This page serves as the definitive source for verified news and official announcements impacting ACB's market position and strategic initiatives.
Access real-time updates including quarterly earnings, regulatory compliance milestones, product launches, and partnership agreements. Investors will find essential details on operational expansions, while analysts gain insights into ACB's research-driven approach to cannabis cultivation and global distribution strategies.
Key coverage areas span clinical trial developments, international market entries, sustainability initiatives, and innovations in cannabis-derived health products. All content is curated to meet investor-grade reliability standards, sourced directly from company filings and accredited industry publications.
Bookmark this page for streamlined access to ACB's evolving narrative in the global cannabis sector. Combine our updates with Stock Titan's financial tools to monitor market reactions and long-term trends.
Aurora Cannabis (NASDAQ: ACB) has announced the filing and distribution of its management information circular for the upcoming annual general and special meeting of shareholders. The virtual meeting is scheduled for August 8, 2025, at 1:00 p.m. ET and will be conducted via live webcast.
The circular is now available on Aurora's website and SEDAR+, with materials being mailed to shareholders of record as of June 16, 2025. Shareholders are urged to vote by the deadline of August 6, 2025, at 1:00 p.m. ET. The board recommends voting FOR all director nominees and meeting resolutions.
Shareholders requiring assistance with voting can contact Laurel Hill Advisory Group, Aurora's proxy solicitation agent, through their toll-free number or email.
Aurora Cannabis (NASDAQ: ACB) has expanded its medical cannabis compassionate pricing program in Canada by increasing the yearly income eligibility threshold from $40,000 to $60,000 CAD. This expansion makes Aurora's program the most inclusive medical cannabis pricing plan in Canada, potentially benefiting over half of the country's adult population.
The company has also introduced new medical cannabis products including Aurora | Mediora Minis (Cannatonic CBD Flower), Daily Special | Sativa J's (THC Pre-Rolls), and WMMC | Seasonal Stash Petro Biscuit (THC Flower). Aurora continues to provide resources for seniors, pediatric patients, veterans, and first responders through their medical cannabis program.
Aurora Cannabis (NASDAQ: ACB) has announced the launch of two new high-potency medical cannabis products in Poland. The company will introduce Farm Gas (27% THC) on June 30 and Sourdough (29% THC) in early August 2025, representing the highest potency medical cannabis products in the Polish market.
Both proprietary cultivars are grown in Aurora's Canadian GACP and EU-GMP facilities. Farm Gas, bred from Sour Diesel and GMO genetics, features a unique terpene profile with limonene and caryophyllene. Sourdough, derived from Cake and Diesel genetics, offers distinct sour and gasoline notes with high THC content.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), Canada's largest medical cannabis company, has announced its participation in TD Cowen's 9th Annual Future of the Consumer Conference in New York City. CFO Simona King will engage in a fireside chat and investor meetings on June 3, 2025, at 2:45pm EST.
The discussion, hosted by TD Cowen's VP of Equity Research Derek Lessard, will focus on Aurora's international market expansion, medical cannabis landscape developments, Canadian manufacturing progress, and market dynamics. A live audio webcast will be available, with replay access for approximately 90 days through Aurora's investor relations website.
Aurora Cannabis has completed a $3 million investment in its Pemberton, British Columbia manufacturing facility, now renamed to Aurora Alpine. The multi-year upgrades have significantly improved the facility's performance, combining proprietary genetics with advanced engineering to optimize cultivation conditions.
Key achievements include:
- Doubled yield and potency, reaching 33.7% record levels
- GACP certification enabling international exports
- Enhanced operational efficiency and cultivation precision
The facility, formerly known as Whistler Medical Marijuana Company, was licensed in 2019. Located overlooking Mount Currie in the Pemberton Valley, the renamed Aurora Alpine reflects the company's commitment to excellence in cannabis production. The improvements strengthen Aurora's position as a global leader in medical cannabis, particularly in international markets through its premium product exports.